NCT07259278 Intelligent Management Platform for Guiding Exercise Rehabilitation in Coronary Heart Disease Patients
| NCT ID | NCT07259278 |
| Status | Recruiting |
| Phase | — |
| Sponsor | China National Center for Cardiovascular Diseases |
| Condition | Secondary Prevention of Coronary Heart Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2025-12-01 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to find out if an artificial intelligence (AI)-enabled stratified management platform can help adults with coronary heart disease (CHD) better perform exercise rehabilitation and manage their health after being discharged from the hospital. The main questions it aims to answer are: 1. Does using the AI platform lead to a greater improvement in exercise capacity (measured by peak oxygen consumption, VO2peak) after 3 months? 2. Does the platform help increase daily physical activity, improve exercise adherence and motivation, and better control modifiable cardiovascular risk factors? 3. Is guiding home-based exercise with this platform safe for low-risk CHD patients? Researchers will compare the AI Management Group (using the platform and a sports wristband) to the Routine Management Group (receiving usual care without the platform) to see if the AI group shows more significant improvements in fitness and health metrics. Participants will: 1. Be randomly assigned to either use the AI platform or receive usual post-discharge care. 2. Receive a personalized exercise prescription from a doctor before going home. 3. If in the AI group: Use the smartphone app and wearable device to track health data for comprehensive post-discharge management, and receive reminders and immediate safety alerts. 4. Attend a follow-up visit at 3 months for check-ups and tests, including an exercise test and health assessments. The study hopes to show that this intelligent management platform is an effective and safe tool to help people with CHD recover at home, stay active, and reduce future heart risks.
Eligibility Criteria
Inclusion Criteria: * CHD patients aged over 18 years; * Stratified as low-risk for cardiovascular events during exercise and classified as low-risk according to the GRACE risk score. * Ability of the patient or close relatives to use smartphones and applications; * Willingness to participate and sign the informed consent form. Exclusion Criteria: * Residual stenosis of \>50% in the left main coronary artery, or \>70% stenosis in other major epicardial vessels; * Planned coronary revascularization within the next 3 months; * Acute myocardial infarction within the past 1 month; * Severe cognitive impairment; * Severely impaired exercise capacity. * Advanced-stage malignancy; * Life expectancy less than 3 months; * Severe multi-organ failure; * Other conditions deemed unsuitable for home-based exercise rehabilitation following assessment by a specialist rehabilitation physician. * Refusal to provide written informed consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07259278 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Secondary Prevention of Coronary Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07259278 currently recruiting?
Yes, NCT07259278 is actively recruiting participants. Contact the research team at sophie_gao@sina.com for enrollment information.
Where is the NCT07259278 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07259278 clinical trial?
NCT07259278 is sponsored by China National Center for Cardiovascular Diseases. The trial plans to enroll 200 participants.